Aeterna Zentaris is a specialty biotech company commercializing and developing therapeutic and diagnostic tests, particularly for growth hormone deficiency.
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
https://t.co/Sr2GohNH78
$AEZS #Diagnostics#GrowthHormoneDeficiency#GrowthHormone
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
https://t.co/PuXwsdhLbU
$AEZS #Diagnostics#Therapeutics
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
https://t.co/N8exzpzZ3v
$AEZS $CZO @ceapro_inc #Diagnostics#Therapeutics
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
https://t.co/2dtDAKZ9SZ
@Ceapro_Inc $CZO $AEZS